Recombinant Anti-FOXO1A antibody [EP927Y] (ab52857)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EP927Y] to FOXO1A
- Suitable for: IHC-P, ICC/IF, Flow Cyt, WB
- Reacts with: Mouse, Human
Overview
-
Product name
Anti-FOXO1A antibody [EP927Y]
See all FOXO1A primary antibodies -
Description
Rabbit monoclonal [EP927Y] to FOXO1A -
Host species
Rabbit -
Specificity
ab52857 recognizes both phosphorylated and unphosphorylated FOXO1A. The immunogen used for this product shares 85% homology with FOXO3. Cross-reactivity with this protein has not been confirmed experimentally. -
Tested Applications & Species
Application Species Flow Cyt HumanICC/IF HumanIHC-P HumanWB Mouse -
Immunogen
Synthetic peptide within Human FOXO1A (phospho S329). The exact sequence is proprietary.
-
Positive control
- WB: NIH/3T3 cell lysate. IHC-P: Human bladder carcinoma tissue. ICC/IF: HeLa cells. Flow Cyt: HeLa cells.
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at -20°C. Stable for 12 months at -20°C. -
Storage buffer
pH: 7.20
Preservative: 0.01% Sodium azide
Constituents: 9% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, 50% Tissue culture supernatant -
Concentration information loading...
-
Purity
Tissue culture supernatant -
Clonality
Monoclonal -
Clone number
EP927Y -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Assay kits
-
Compatible Secondaries
-
Isotype control
-
Positive Controls
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab52857 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Tested applications are guaranteed to work and covered by our Abpromise guarantee.
Predicted to work for this combination of applications and species but not guaranteed.
Does not work for this combination of applications and species.
Application | Species |
---|---|
Flow Cyt |
Human
|
ICC/IF |
Human
|
IHC-P |
Human
|
WB |
Mouse
|
All applications |
Rat
|
Application | Abreviews | Notes |
---|---|---|
IHC-P | (1) |
1/250 - 1/500. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
|
ICC/IF |
1/100 - 1/250.
|
|
Flow Cyt |
1/90.
|
|
WB | (5) |
1/1000 - 1/10000. Detects a band of approximately 80 kDa (predicted molecular weight: 70 kDa).
|
Notes |
---|
IHC-P
1/250 - 1/500. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol. |
ICC/IF
1/100 - 1/250. |
Flow Cyt
1/90. |
WB
1/1000 - 1/10000. Detects a band of approximately 80 kDa (predicted molecular weight: 70 kDa). |
Target
-
Function
Transcription factor which acts as a regulator of cell responses to oxidative stress. In the presence of KIRT1, mediates down-regulation of cyclin D1 and up-regulation of CDKN1B levels which are required for cell transition from proliferative growth to quiescence. -
Tissue specificity
Ubiquitous. -
Involvement in disease
Defects in FOXO1 are a cause of rhabdomyosarcoma type 2 (RMS2) [MIM:268220]. It is a form of rhabdomyosarcoma, a highly malignant tumor of striated muscle derived from primitive mesenchimal cells and exhibiting differentiation along rhabdomyoblastic lines. Rhabdomyosarcoma is one of the most frequently occurring soft tissue sarcomas and the most common in children. It occurs in four forms: alveolar, pleomorphic, embryonal and botryoidal rhabdomyosarcomas. Note=Chromosomal aberrations involving FOXO1 are found in rhabdomyosarcoma. Translocation (2;13)(q35;q14) with PAX3; translocation t(1;13)(p36;q14) with PAX7. The resulting protein is a transcriptional activator. -
Sequence similarities
Contains 1 fork-head DNA-binding domain. -
Post-translational
modificationsPhosphorylated by AKT1; insulin-induced (By similarity). IGF1 rapidly induces phosphorylation of Ser-256, Thr-24, and Ser-319. Phosphorylation of Ser-256 decreases DNA-binding activity and promotes the phosphorylation of Thr-24, and Ser-319, permitting phosphorylation of Ser-322 and Ser-325, probably by CK1, leading to nuclear exclusion and loss of function. Phosphorylation of Ser-329 is independent of IGF1 and leads to reduced function. Phosphorylated upon DNA damage, probably by ATM or ATR. -
Cellular localization
Cytoplasm. Nucleus. Shuttles between cytoplasm and nucleus. - Information by UniProt
-
Database links
- Entrez Gene: 2308 Human
- Entrez Gene: 56458 Mouse
- Entrez Gene: 84482 Rat
- Omim: 136533 Human
- SwissProt: Q12778 Human
- SwissProt: Q9R1E0 Mouse
- SwissProt: G3V7R4 Rat
- Unigene: 370666 Human
see all -
Alternative names
- FKH 1 antibody
- FKH1 antibody
- FKHR antibody
see all
Images
-
Anti-FOXO1A antibody [EP927Y] (ab52857) at 1/1000 dilution + NIH/3T3 cell lysate at 10 µg
Secondary
Goat anti-rabbit HRP at 1/2000 dilution
Predicted band size: 70 kDa
Observed band size: 70 kDa -
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-FOXO1A antibody [EP927Y] (ab52857)
ab52857 at 1/250 dilution staining FOXO1A in human bladder carcinoma by Immunohistochemisty, Paraffin embedded tissue.
Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
-
ab52857 at 1/100 dilution staining FOXO1A in HeLa cells by Immunocytochemistry.
-
Flow cytometry analysis of HeLa (human cervix adenocarcinoma) cells labeling FOXO1A (red) with ab52857 at a 1/90 dilution. Cells were fixed with 4% paraformaldehyde and permeabilized with 90% methanol. A goat anti-rabbit IgG (Alexa Fluor® 488) (ab150077) was used as the secondary antibody at a 1/2000 dilution. Black - Rabbit monoclonal IgG (ab172730). Blue (unlabeled control) - Cells without incubation with the primary and secondary antibodies.
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
References (49)
ab52857 has been referenced in 49 publications.
- Zhang J et al. Down-regulation of LINC00472 promotes osteosarcoma tumorigenesis by reducing FOXO1 expressions via miR-300. Cancer Cell Int 20:100 (2020). PubMed: 32256209
- Zhang J et al. N1-Methylnicotinamide Improves Hepatic Insulin Sensitivity via Activation of SIRT1 and Inhibition of FOXO1 Acetylation. J Diabetes Res 2020:1080152 (2020). PubMed: 32280711
- El-Merahbi R et al. The adrenergic-induced ERK3 pathway drives lipolysis and suppresses energy dissipation. Genes Dev 34:495-510 (2020). PubMed: 32139423
- Tian F et al. MiR-542-5p Inhibits Hyperglycemia and Hyperlipoidemia by Targeting FOXO1 in the Liver. Yonsei Med J 61:780-788 (2020). PubMed: 32882762
- Shu Q et al. Acupuncture Targeting SIRT1 in the Hypothalamic Arcuate Nucleus Can Improve Obesity in High-Fat-Diet-Induced Rats with Insulin Resistance via an Anorectic Effect. Obes Facts 13:40-57 (2020). PubMed: 31935731